News
1h
Zacks Investment Research on MSNHims & Hers Leads the Charge in AI-Powered Personalized HealthcareThe renowned health and wellness platform, Hims & Hers Health, Inc. HIMS, is building a next-generation, digital-first healthcare platform centered around personalization, accessibility and ...
ClaimsFiler, a FREE shareholder information service, reminds investors that they have until August 25, 2025 to file lead plaintiff applications in securities ...
Rachel Sacks is a freelance writer and copywriter with over 10 years of experience writing about health and wellness, ...
Danish leader will face a challenging landscape among competitors ...
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Hims & Hers Health, Inc. (NYSE: HIMS) between April 29, 2025 and June 23, 2025, both dates inclusive (the ...
21h
Zacks Investment Research on MSNPulmonx Corporation (LUNG) Reports Q2 Loss, Beats Revenue EstimatesPulmonx Corporation (LUNG) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.4. This compares to a loss of $0.39 per share a year ago. These figures ...
Shareholders who purchased shares of HIMS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required ...
Law Offices of Howard G. Smith continues its investigation on behalf of Novo Nordisk A/S ("Novo Nordisk" or the "Company") (NYSE: NVO) investors concerning the Company's possible violations of federal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results